15 results about "Retinal Cones" patented technology

The invention belongs to the technical field of medicines, and particularly relates to application of Comput-8 in preparation of a product for relieving or treating retina degeneration induced by blue light damage. It is found for the first time that Compond-8 has a protection effect on retina rod cells and cone cells induced by blue light damage, the cilia length, density and membrane disc thickness of the cone cells and the rod cells can be increased, the thickness of a retina outer nuclear layer can be increased, photoreceptor cell damage caused by blue light exposure can be remarkably improved, and the photoreceptor cell damage can be remarkably reduced. The retina degeneration caused by blue light injury can be relieved or treated, and a new thought and means are provided for treatment of the retina degeneration induced by the blue light injury.

The application discloses an auxiliary visual light device of mixed light, which mixes the light emitted by different color temperature light emitting units of a mixed light source module, forms a visual effect under the action of the mixed light, and can effectively stimulate the rod cells and cone cells on the retina, which are two kinds of photosensitive visual cells, compared with the prior art, the light intensity of the mixed light can break through to the retina of the eye, and the rod cells and the cone cells respectively dominate dark vision activity and bright vision activity. Therefore, the auxiliary visual light device of mixed light can assist users in visualizing objects, reading books and newspapers, and other visual activities, and provides a new scheme for assisting the human eye to clearly see objects on the level of light technology, in addition to wearing corresponding special glasses to correct, to help solve the problem of unclear vision caused by myopia, hypermetropia, presbyopia and other reasons. Moreover, the wavelength of the light generated by each light emitting unit is greater than 450nm, which can avoid the harm of blue light.

The application discloses a medical goggle lens and a design method thereof, and belongs to the field of goggle lenses. According to the corresponding curves x(lambda), y(lambda) and z(lambda) of three cone cells of a human eye to a visible spectrum, three stimulus values are obtained by using a standard observer response function, the three stimulus values are normalized, the chroma is less than 0.1, the value range of x, y and z is 0.32-0.34, the laser wavelength to be cut off is obtained, the transmittance of other wavelengths is adjusted, corresponding x, y and z design values are obtained, the film system of an optical film is designed according to the x, y and z design values, and the corresponding film system is obtained. Through the above steps, the laser wavelength used in surgery is cut off in a specific wavelength range, the radiation of laser light is prevented from causing harm to the human eye, the transmittance is high, the chromatic aberration is small, the color of the film layer is close to colorless, and the color of the protective lens is reduced to interfere with medical staff.

The application provides a detection method for the effect of longitudinal chromatic aberration defocus signals on eye refraction development, which comprises the following steps: obtaining a spectral sensitivity function of human eye cone cells; obtaining a first target defocus signal based on the spectral sensitivity function; performing an influence experiment of a display image longitudinal chromatic aberration defocus signal on human eyes based on the spectral sensitivity function, and obtaining a second target defocus signal; performing an animal level in-vivo detection experiment based on the spectral sensitivity function, and obtaining a third target defocus signal; and performing a molecular level analysis experiment of the effect of the image longitudinal chromatic aberration defocus signal on eye refraction development based on the in-vivo detection experiment. The method provided in the embodiments of the application can analyze the effect of DI-LCA defocus signals on refraction development through cone cells from three levels of tissues, animals and molecules, and preferably target defocus signals, thereby providing support for the research and development of display driving programs and devices for reducing the risk of myopia.

This invention discloses the application of the VDAC2 gene or VDAC2 protein as a target in screening drugs for the treatment of retinitis pigmentosa, relating to the field of biomedical technology. The drug is one that reduces the expression level of the VDAC2 gene or inhibits the expression level or activity of the VDAC2 protein; the CDS sequence of the VDAC2 gene is shown in SEQ ID NO.1. This invention uses a rod cell-specific promoter to inhibit VDAC2 expression, which can significantly improve the survival rate of local photoreceptor cells. This method intervenes in the early stages of the disease, conforming to the natural course of RP. It strengthens the function of rod cells before a large number of photoreceptor cells die, delaying their degenerative process and indirectly protecting cone cells, thereby prolonging the patient's effective visual retention time. This overcomes the shortcomings of existing gene therapies, which are mainly applicable to late-stage or specific mutation types, and provides a therapeutic basis for retinitis pigmentosa.

The application discloses a multifunctional visual acuity prevention and control wearable device based on a sound wave factor, which comprises an eye protection frame body and an adjustable elastic band connected with the eye protection frame body; a control module and a power module are arranged in the eye protection frame body; a plurality of sound wave resonance generators corresponding to the acupoints of the human eyes are arranged outside the eye protection frame body; the power module is electrically connected with the control module and the sound wave resonance generators respectively. The application further comprises a connection sensing and feedback unit and a frequency regulator connected with the control module. The application discloses a use method of the multifunctional visual acuity prevention and control wearable device based on the sound wave factor. Based on the physical characteristics and biological effects of the sound wave resonance and the resonance effect of the sound wave factor, a series of biological effects are generated on the biological cells and tissues of the acupoints around the human eyes, so that the gene expression of the eye tissues is influenced, the sensitivity of the cone cells and the secretion of dopamine are promoted, the visual recognition ability is optimized, the growth of the eye axis is inhibited, and the prevention and control of the naked eye myopia are achieved.

This invention provides a light source with high chromatic color richness. The high chromatic color richness light source is based on the difference in stimulation patterns of the three types of cone cells in the human eye's color perception mechanism between monochromatic light and mixed light that can be identified as that color. The visible light band from 380nm to 780nm is divided into three bands using 430nm and 680nm as sub-band wavelength values. Furthermore, it is designed based on the emission peak wavelength of LED chips and phosphors using the corresponding LED chips as excitation sources, ensuring the richness of the emission peak wavelengths of the high chromatic color richness light source in each band, thus guaranteeing the chromatic color richness of the light source. Therefore, it is beneficial in the human eye's color perception mechanism to make the chromatic color of the object being observed more similar to that of the observed object, thereby improving the human eye's ability to compare and filter differences in the observed object and providing a natural, realistic, and comfortable visual experience.

This invention discloses the application of disodium 4,4'-diisothiocyanate-2,2'-stilbene sulfonate in the preparation of drugs for the prevention, delay, and / or treatment of blue light-induced retinal damage. It belongs to the field of biomedical technology. This invention demonstrates for the first time that sodium DIDS can effectively protect photoreceptor cells from blue light damage: at the cellular level, sodium DIDS can restore mitochondrial membrane potential, increase ATP levels, reduce reactive oxygen species accumulation, and inhibit mitochondrial-dependent apoptosis; at the animal level, intravitreal injection of sodium DIDS can improve vision in mice exposed to blue light, restore the amplitude of a-waves and / or b-waves in electroretinograms, and protect the outer segment length and outer nuclear layer thickness of cone cells. Sodium DIDS provides a novel therapeutic strategy for blue light-induced retinal photodamage through multi-target synergistic protection of mitochondrial function.

The invention relates to the field of intelligent medical treatment, in particular to an eye disease prediction method and device based on monochromatic light and a program product. Comprising obtaining a monochromatic background light source; the monochromatic background light source flickers at a frequency to perceive the retina of the subject to obtain perceived data; performing eye disease judgment based on the sensing data of the monochromatic light source, when the background light source is red and the sensing data is smaller than a red preset threshold value, predicting that the visual cone cells in the macular region are abnormal, otherwise, predicting that the visual cone cells are normal; when the background light source is green and the sensing data is smaller than a green preset threshold value, determining that the optic nerve conduction of the vertebral body is abnormal, otherwise, determining that the optic nerve conduction is normal; and when the background light source is a yellow light source and the sensing data is smaller than a yellow preset threshold, judging that the retina and the optic nerve are abnormal, otherwise, judging that the retina and the optic nerve are normal. Eye anomaly prediction can be carried out through the monochromatic light source, and the method has good clinical value.

The present invention relates to a nucleic acid having promoter activity in cone cells. The invention also relates to an expression cassette or vector comprising the promoter, a viral particle or cell comprising the expression cassette or vector, and a pharmaceutical composition comprising the expression cassette or vector and the viral particle or cell. The invention also relates to the use of said expression cassette, vector, viral particle, cell or pharmaceutical composition in the treatment of eye diseases, in particular hereditary retinal diseases.

The invention discloses a visual interaction method for splicing processors, and relates to the technical field of man-machine interaction, and the method comprises the steps: tracking a user iris motion track in real time, determining a processor in a current view cone focus region, and marking a processor in a non-focus region outside the view cone focus region; when the node position similarity exceeds a preset verification threshold value, triggering a configuration change command corresponding to execution of the prediction instruction to a marked non-focus area processor; new load data generated by the configuration change command after execution are collected in real time, whether the new load data exceed the preset load threshold value or not is judged again, and a dynamic monitoring and interactive closed loop is formed. According to the method, the pulse spectrum is projected to the peripheral visual field of the retina of a user, a non-intrusive optical signal is formed in the peripheral visual field of the retina by using the infrared spectrum, and the load alarm is transmitted on the premise of not interfering central focus processing of cone cells by using the high sensitivity of the rod cells to a dynamic light source.

The utility model discloses a point diffusion prism lens composite lens, which relates to the technical field of myopic glasses, and comprises a point diffusion lens and a second lens arranged on the inner side or the outer side of the point diffusion lens, and the second lens is selected from one of a combined prism lens, a progressive lens or a defocus lens. The combined prism lens is formed by combining a prism and a convex lens, and the convex lens is located between the prism and the point diffusion lens. The combined prism lens is wedge-shaped, the thicker end of the combined prism lens is a base, and the thinner end of the combined prism lens is a base top. According to the point diffusion prism lens composite lens, the point diffusion lens is respectively compounded with the combined prism lens, the progressive lens or the out-of-focus lens, so that incident light is scattered, soft optical transition is formed in a peripheral view field, and the design reduces the signal intensity difference between adjacent view cone cells, namely, reduces the contrast ratio; therefore, 'elongation signals' transmitted from the retina to the eyeball are inhibited, and eye axis growth is slowed down.

The application belongs to the technical field of medicines, and particularly relates to application of Compound-8 in preparation of products for relieving or treating blue light damage induced retinal degeneration. It is found for the first time that Compound-8 has a protective effect on blue light damage induced retinal rod cells and cone cells, can increase the length, density and disc thickness of the cilia of the cone cells and the rod cells, can increase the thickness of the outer nuclear layer of the retina, significantly improves the photoreceptor cell damage caused by blue light exposure, can relieve or treat the retinal degeneration caused by blue light damage, and provides a new thought and means for the treatment of blue light damage induced retinal degeneration.

This invention relates to TAFA proteins, fragments thereof, or variants thereof that have the ability to increase the length of neurites or branching points. Furthermore, this invention relates to pharmaceutical compositions containing polypeptides comprising the amino acid sequence of said TAFA protein, its fragments, or variants thereof; nucleic acid molecules encoding said polypeptides; vectors carrying said nucleic acid molecules; recombinant viral particles comprising said vector and capsid protein; cells comprising said vector; cells transformed with said vector; or therapeutic uses thereof. The compositions of this invention promote repair from damaged retina (e.g., cone cells of photoreceptors, etc.) or increase the length of neurites in neurons, and are therefore advantageous for the prevention or treatment of retinal neurological disorders and / or neuropathic pain.

Provided is a nucleic acid having promoter activity in a cone cell. Also provided are an expression cassette or vector comprising the promoter, a virus particle or cell comprising the expression cassette or vector, and a pharmaceutical composition comprising the expression cassette or vector and the virus particle or cell. Also provided is a use of the expression cassette, vector, virus particle, cell or pharmaceutical composition in the treatment of eye diseases, especially inherited retinal diseases.